NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Patriot National (“Patriot” or the “Company”) (NYSE: PN) and certain of its officers, on behalf of shareholders who purchased Patriot securities between August 15, 2016 and March 3, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and failed to disclose that: (1) Patriot National special committee was beholden to CEO, Steve Mariano; (2) therefore, the special committee was operating for the benefit of Mariano and not Patriot National or its shareholders; (3) the special committee did not independently assess the merits of the Ebix transaction; (4) the special committee was not exploring strategic alternatives in order to maximize shareholder value; and (5) consequently, defendants’ statements about Patriot National’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/pn, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Patriot you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 458490

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Both companies had active trading sessions on Wednesday, as news of insider buying and optimistic product forecasts drew attention to the two biotech stocks.

RDI Initiates
Coverage:

Pacific Biosciences
of California https://ub.rdinvesting.com/news/?ticker=PACB

Nymox Pharmaceutical
Corporation https://ub.rdinvesting.com/news/?ticker=NYMX

Pacific Biosciences of California advanced 10.93% to close at $5.38 on Wednesday. The stock traded between $5.65 and $4.82 on volume of 3.83 million shares traded. The company designs and manufactures sequencing systems that resolve genetically complex problems. Investors expressed confidence when they looked into Cowen and Company’s results of a 51-lab survey released on Wednesday, which forecasted a bullish environment for next-generation sequencing technology, to rise up to as much as 80% in 2017. Cowen also said that Pacific Biosciences’ sequencing franchise is “making steady improvements” and this gear works best for small volume.

On February 2nd of this year, the company announced its 4th quarter results for 2016 where revenues totaled $25.7 million compared to $36.3 million for the same reporting period in 2015 and the company has reported a loss of $19.0 million or $0.21 a share for the fourth quarter of 2016 as compared to loss of $1.4 million or $0.02 a share in same reporting period of 2015. However looking at granular level data, larger part of revenues was of contractual revenues from Roche in the fourth quarter of 2015 as compared to larger portion of revenues was of core products’ sales in the fourth quarter of 2016. Pacific Biosciences’ product and service revenue for the 2016 4th quarter increased 92.2% to $24.4 million, compared to $12.7 million for the same reporting period in 2015. Pacific Biosciences reported gross profit for the 4th quarter of 2016 was $11.4 million, compared with a $26.5 million gross profit one year earlier. The company has witnessed a numbers of insider buying in the current quarter. As the consensus of analysts has called for “overweight” rating on the company, the company witnessed rise of 11.16 percent in its market price since the release of 4th quarter result.

Access RDI’s Pacific Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=PACB

Nymox Pharmaceutical advanced 11.56% to close at $3.57 on Wednesday. The stock traded within a one dollar range at $4.10 and $3.15 on volume of 1.86 million shares traded. The company is expected to begin the process of submitting its initial filing that will seek approval for Fexapotide Triflutate, its BPH drug, in the next few weeks. On March 29th, Nymox Director James Robinson who regularly purchased shares of the company in last couple of years, purchased another 50,000 shares of the company at prices ranging from $3.49 to $3.60 per share. He now owns 3,317,950 shares of the company.

The FDA trial designation for Fexapotide Triflutate, NX-1207, is a drug used for the treatment of BPH. It can be administered by an urologist as an outpatient procedure in only a few minutes without requiring any type of anesthesia and little or discomfort is associated with the procedure. The company website notes that results of the Phase II trials show “men treated with NX-1207 reported statistically significant improvement in BPH symptoms 3 and 6 months after a single NX-1207 treatment with no reported serious drug-related side effects, including no (0%) significant sexual side effects. Patients notice improvement as early as a week or two after treatment.” Additionally, NX-1207 treatments do not require the patient to adhere to a daily regimen of pills for the rest of a patient’s life.

Access RDI’s Nymox Pharmaceutical Research Report at: https://ub.rdinvesting.com/news/?ticker=NYMX

Our Actionable Research on Pacific Biosciences of California (NASDAQ: PACB) and Nymox Pharmaceutical Corporation (NASDAQ: NYMX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458552

WASHINGTON, DC / ACCESSWIRE / March 30, 2017 / Fifty publicly traded oil, natural gas, and service company leaders will present their financial portfolios next week to Wall Street analysts, money managers, and capital providers at the 23rd annual Oil & Gas Investment Symposium New York (OGIS New York), presented by the Independent Petroleum Association of America (IPAA). The conference will take place April 3-4, 2017, at the Sheraton New York Times Square in New York City.

The event will draw over 1,300 attendees this year. Analysts and investors will also have the opportunity to meet face-to-face with presenting company executives during breakfasts, breakout sessions, receptions, and corporate hosted dinners.

On Monday, April 3rd, the keynote address will be given by Jarand Rystad, founder and managing partner at Rystad Energy, who will speak on “The Evolution of Shale Oil: What Drives High Performance and Where are We Heading?” On Tuesday, April 4th, IPAA and NASDAQ will host a special seminar: “Preparing for a Successful Pre- and Post-IPO,” including sessions on preparing for the journey, lessons learned, and taking a best practices approach to investor relations from leading industry executives and financial advisors.

Details, registration, and schedules for all events can be found at www.ipaa.org/meetings.

News Compliments of ACCESSWIRE.

Executives from the following companies are scheduled to participate in OGIS
New York:

Abraxas Petroleum Corporation; Approach Resources Inc.; Blackbird Energy Inc.; BNK Petroleum (US) Inc.; California Resources Corporation; Callon Petroleum Company; Camber Energy, Inc.; Carrizo Oil & Gas, Inc.; Contango Oil & Gas; Earthstone Energy, Inc.; Eclipse Resources; EcoStim Energy Solutions; Evolution Petroleum Corp.; Flotek Industries; Foothills Exploration, Inc.; Gastar Exploration Inc.; Goodrich Petroleum; Houston American Energy; Hyperdynamics Corporation; Jones Energy, Inc.; Legacy Reserves LP; Lilis Energy; Lonestar Resources; Matador Resources Company; Midstates Petroleum Company Inc.; Northern Oil & Gas, Inc.; Oasis Petroleum Inc.; Panhandle Oil and Gas Inc.; PDC Energy, Inc.; PetroQuest Energy, Inc.; Pioneer Natural Resources; Profire Energy, Inc.; Resolute Energy Corporation; RMP Energy Inc.; Rosehill Resources; Samson Oil & Gas Limited; Sandridge Energy, Inc; SM Energy; Southwestern Energy Company; SRC Energy Inc.; Sundance Energy, Inc.; Torchlight Energy Resources, Inc.; TransAtlantic Petroleum Corp.; Unit Corporation; VAALCO Energy, Inc.; W&T Offshore, Inc.; Western Sands LLC; Whiting Petroleum Corporation; Wildhorse Resource Development; Yuma Energy, Inc.

SOURCE: IPAA

ReleaseID: 458505

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The Rangers are moving to Las Vegas, and casino stocks are reacting astronomically well. Both Las Vegas Sands and Wynn Resorts’ stock prices registered gains by the end of business yesterday. Trade volumes are expected to rise significantly, with almost every other industry player deeming the move one of the best things to happen to Las Vegas in recent times. Casino stocks could remain up as mid-year approaches. Gaming wins in the Las Vegas strip downed last month with revenues increasing by slightly less than 9%. Here’s a closer look at the day’s happenings in the casino industrial sector.

RDI Initiates
Coverage:

Las Vegas Sands Corp. https://ub.rdinvesting.com/news/?ticker=LVS

Wynn Resorts, Limited https://ub.rdinvesting.com/news/?ticker=WYNN

The casino and resort operating company closed the day on a high, with the stock gaining 0.56% to close the day at $57.25. The upsurge is a reflection of the recent Raiders move to Nevada. The gambling mecca is set to reap heavily from the move, with its stock price comfortably going up by the day.

When the Raiders move to the desert, casino attendance will imminently go up, meaning more business for casinos. The direct effect on the stock price is already taking shape, with Wall Street analysts deeming the move “the most anticipated in recent times”. Boyd Gaming Corp and Capri Casinos Inc.’s shares are also setting new heights by the day.

Access RDI’s Las Vegas Sands Research Report at: https://ub.rdinvesting.com/news/?ticker=LVS

Wynn Resorts’ shares closed the day on a positive, to trade at $115.49, a 0.27% increase from the previous day’s value. There is no denying the Raiders’ move to Las Vegas will have a desirable effect for the casino industry. The plans to build a 65,000 capacity stadium are at the implementation stage, with the Raiders having already met the $750 million budget. Speaking to Wall Street Journal, Chief Executive Steve Wynn called the move “a game changer”.

The upsurge in stock prices in the industry is expected to continue, with industry experts speculating a positive reaction by investors; both current and potential.

Access RDI’s Wynn Resorts Research Report at: https://ub.rdinvesting.com/news/?ticker=WYNN

Our Actionable Research on Las Vegas Sands Corp. (NYSE: LVS) and Wynn Resorts, Limited (NASDAQ: WYNN) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458550

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Wednesday was a relatively calm day for the markets the NASDAQ closed at 5,897.55, a positive change of around 0.38 percent. The Dow Jones, on the other hand, didn’t manage to get into the green zone, closing in at around 20,659.32, a negative change of around 0.20 percent. The market didn’t see major slumps or growths for the most part, with the most notable news coming in for Ford, which is recalling as many as 441,000 vehicles.

RDI Initiates
Coverage:

Sirius XM Holdings
Inc. https://ub.rdinvesting.com/news/?ticker=SIRI

Pandora Media Inc. https://ub.rdinvesting.com/news/?ticker=P

Sirius XM shares gained 0.59 percent to close at $5.14. The stock traded in a range of $5.09 to $5.14 on volume of 16.9 million shares traded. The stock is still a bit away from its 52 weeks high of $5.53. Average analyst expectations have called for a price target of around $5.25 for the company, which is below the 52-week high. Last week, Barclays analyst Kannan Venkateshwar lowered Sirius XM’s rating to “equal weight” from “overweight” and also gave a price target of $4.90 a share. Shares of Sirius have gained approximately 15.5 percent year-to-date.

Access RDI’s Sirius XM Research Report at: https://ub.rdinvesting.com/news/?ticker=SIRI

Pandora Media experienced a bit of a topsy-turvy day. The stock rose to around $12 during the day from its previous close of $11.70, before falling and closing in at $11.91. While the period between March 8 to March 14 saw a quick rally for the stock, it has been around the same value ever since. On March 13th, the company announced its on-demand music streaming subscription, Pandora Premium.

“Every day tens of millions of people trust us to choose the exact right songs for them. That’s why they spend more time with Pandora than any other music service,” said Tim Westergren, founder and CEO of Pandora. “With Premium, we’re leveraging our immense trove of data and everything we’ve learned about personalization to offer a listening experience that sets a new standard for what a music service should be.”

Access RDI’s Pandora Media Research Report at: https://ub.rdinvesting.com/news/?ticker=P

Our Actionable Research on Sirius XM Holdings Inc. (NASDAQ: SIRI) and Pandora Media Inc. (NYSE: P) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458549

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The markets weren’t really what you would call bullish yesterday. Barring a few, most of the stocks seeing changes of as little as 0.2-0.5%, either in the green or the red. That pretty much summed up Dow Jones and NASDAQ as well, which closed just 0.20% down and 0.38% up respectively. The only major news that came in through the day was that Ford has decided to recall as many as 441,000 vehicles.

RDI Initiates Coverage:

Catalyst Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=CBIO

Pernix Therapeutics
Holdings Inc. https://ub.rdinvesting.com/news/?ticker=PTX

Catalyst Biosciences Inc. didn’t really have a great day. On an otherwise normal day, the stock managed to lose as much as 29.98%. It opened at around $17.80 near touched the high of $18.10 but by the end of the day, the stock fell to $10.51. The company last month completed a reverse stock split of one-for-fifteen, after its shares fell to a value of $4.73. The company’s shares traded at around $24.90 a year back on March 30, 2016. After the reverse split, it rose above $15 but has again fallen to the $10 mark.

On March 28th, the company announced that CB 2679d/ISU304, a highly potent next-generation coagulation Factor IX variant, has received the Investigational New Drug Application (IND) approval from the Korean Ministry of Food and Drug Safety (MFDS).

Access RDI’s Catalyst Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=CBIO

Pernix Therapeutics shares fell 13.05% to close at $3.53 a share. The stock traded in a range of $3.08 to $3.67 a share on volume of 643,700 shares traded. Last December, the shares fell to a record low of $1.94, which was just above the $1 bid price that the company needed to be eligible to be listed on the NASDAQ stock exchange. It seems that the 42% gains the company made in share prices after winning its patent case against generic from Actavis Labs is being wiped out. It remains to be seen whether the downward trend will continue further or we have reached the threshold point.

Access RDI’s Pernix Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PTX

Our Actionable Research on Catalyst Biosciences Inc. (NASDAQ: CBIO) and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458547

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Orexigen has released their 2016 fourth quarter results. The revenues are surprisingly soaring high, but the stocks are currently not doing as well as expected in the market. VIVUS on the other hand seeks to reacquire commercialization rights for its erectile dysfunction drug from Sanofi. The acquisition involves its markets in Africa, Turkey, the Middle-East and Commonwealth of Independent States, including Russia. VIVUS has lost 3.5% of its stock value this year, and the reacquisition of its rights has been termed as strategic to cushion further reductions in the stock price.

RDI Initiates
Coverage:

Orexigen
Therapeutics, Inc. https://ub.rdinvesting.com/news/?ticker=OREX

VIVUS, Inc. https://ub.rdinvesting.com/news/?ticker=VVUS

The pharmaceutical company’s stocks dipped 5.90% by the end of business yesterday, to trade at $3.99. The company is currently struggling to break even, with the value of stocks plummeting to $1.67 a share in December 2016 from $6.4 in June 2016. Quarterly profits however remained high, as the company registered $13.9 in revenue at the end of 2016.

While releasing the quarterly results, CEO Mike Narachi cited an increase in sales, even though the stock price is on a free fall. The company has announced that in 2017 it expects a cash balance of between $40 million and $50 million. The company also expects operating expenses to range from $115 million to $125 million. With regard to Zacks rank, Orexigen is at number 3 (hold), with Heska Corporation and Addus HomeCare Corp being the highest ranked stocks.

Access RDI’s Orexigen Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=OREX

VIVUS’ shares recovered from a significant dip yesterday, to close yesterday at $1.11, a 1.85% increase from Tuesday’s closing value. According to Zacks Equity Research, the company recently announced the completion of an agreement to retrieve the commercial rights of its erectile dysfunction drug Stendra from Sanofi SNY.

VIVUS will acquire commercialization rights involving the African market, Middle East, Turkey and Commonwealth of independent states including Russia. Sanofi is expected to ease out the transition process, with regard to regulatory requirements especially in the Russian and Middle East markets. The reacquisition proved imminent with investors saying the move couldn’t have come at a better time.

Access RDI’s VIVUS Research Report at: https://ub.rdinvesting.com/news/?ticker=VVUS

Our Actionable Research on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and VIVUS, Inc. (NASDAQ: VVUS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458546

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / Microsoft’s plans to close its Sweden Skype offices are at the finalization stages. The move is part of a long term strategy to reduce the geographic spread of Skype. Microsoft says plans are underway to close some of its offices in select countries. Cisco is currently on an all-out war with Arista Networks. Cisco is planning to change its sales strategy to attract clients who do not desire to purchase high-end hardware together with the operating system.

RDI Initiates
Coverage:

Microsoft Corporation https://ub.rdinvesting.com/news/?ticker=MSFT

Cisco Systems, Inc. https://ub.rdinvesting.com/news/?ticker=CSCO

Microsoft’s stocks surged 0.28% yesterday, to close trading at $65.47. The company has confirmed closure of its Skype offices in Sweden, in a newly released report. The closure comes amid reports of the tech giant’s long-term plan to cap the geographical spread of Skype’s offices. The Stockholm branch has been consistent with revenues, registering a $28 million (SEK 250 million) turnover last year.

Talks with relevant trade unions are ongoing, with the closure affecting 120 employees who are set to lose their jobs. A Microsoft spokesman said the move was “difficult”, but lines up with the company’s long term “geographic footprint reduction ambitions”.

Access RDI’s Microsoft Research Report at: https://ub.rdinvesting.com/news/?ticker=MSFT

Cisco’s stocks have been dipping since the start of trading earlier yesterday. The stock price closed on a negative, registering a 0.82% dip to settle at $33.74. Cisco is planning to change its selling strategy in a bid to offset competition from Arista Networks. The strategy, announced by The Information in a newly released report, involves Cisco selling its operating system to customers without the need for a purchase of its high-end hardware equipment.

Investors deem the move a positive, bearing the potential to lure in Microsoft and Facebook, the biggest internet technology corporations. The move is an all-out war for market domination, amid the patent litigation between the Cisco and Arista for the lion’s share of networking and cloud computing industry. The news comes amid the Cisco-Arista patent litigation case with the International Trade Commission.

Access RDI’s Cisco Research Report at: https://ub.rdinvesting.com/news/?ticker=CSCO

Our Actionable Research on Microsoft Corporation (NASDAQ: MSFT) and Cisco Systems, Inc. (NASDAQ: CSCO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458545

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The social media power and e-commerce presence of their respective industries has Facebook and Amazon at the head of the class. As both companies have shown, there are hidden forces at work in India that are bringing competitive opposition on their toes. Amazon continues with its local store strategy, while Facebook looks to minimize the impact of a potential social media threat.

RDI Initiates
Coverage:

Amazon.com, Inc. https://ub.rdinvesting.com/news/?ticker=AMZN

Facebook Inc. https://ub.rdinvesting.com/news/?ticker=FB

Amazon.com advanced 2.14% to close at a record high $874.32 on Wednesday. The stock traded in a wide range on the day, between $876.44 and $859.02 on volume of 4.49 million shares traded. Amazon has been credited with its market dominance as an e-commerce behemoth as the basis for its record price surge. After the close of the markets, the company announced a second Houston area Fulfillment Center that is expected to create 1,000 full time jobs.

The company announced that it is going to eliminate its unprofitable Quidsi unit seven years after the company decided to acquire it in 2011 for nearly $500 million. The company, whose primary product was shipping diapers for free, was believed to give Amazon.com an opportunity to increase their online presence in the household goods e-commerce niche. An Amazon spokesperson said, “We have worked extremely hard for the past seven years to get Quidsi to be profitable, and unfortunately we have not been able to do so.” Some current employees will retain their jobs, such as its software development team who will be moved to AmazonFresh, but 263 employees will be laid off.

Access RDI’s Amazon.com Research Report at: https://ub.rdinvesting.com/news/?ticker=AMZN

Facebook advanced 0.63% to close at $142.65 on Wednesday. The stock traded in a narrow range between $142.86 and $141.83 on volume of 16.53 million shares traded. One of the top reasons for the small bump in stock price is the company’s continued digital assault on competitor Snap, whose application, Snapchat has been increasingly popular. Facebook owns Instagram, and whether as a competitor in advertising or in friend connections, Facebook obviously believed that reducing the competition before too many users strayed from Facebook was the right strategy. On March 22nd, FB’s Instagram has crossed mark of 1 million active advertisers targeting it’s 600 million plus monthly active users.

In advertising related news, Congress has sent President Donald Trump legislation that would roll back consumer privacy protections and will allow internet providers to sell browsing habits of their users to advertisers. Under former President Obama, broadband companies were required to get a customer’s permission to market their app and web-browsing history to third parties. This means that broadband companies will be able to sell the data to the highest bidder – or 1,000 interested parties. One effect of this bill is that Facebook marketing data will likely be diluted. Right now, internet companies like Google and Facebook don’t have to ask user’s permission before tracking what sites they visit, but with this bill, broadband providers like AT&T, Comcast and Verizon will also be able to do the same.

Access RDI’s Facebook Research Report at: https://ub.rdinvesting.com/news/?ticker=FB

Our Actionable Research on Amazon.com, Inc. (NASDAQ: AMZN) and Facebook Inc. (NASDAQ: FB) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458556

CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / March 30, 2017 / CPR Cell Phone Repair, the largest and fastest growing retail mobile device repair franchise network in North America, is pleased to announce the opening of a new store in Wylie, TX. CPR Cell Phone Repair congratulates Area Developer Amin Lakhani on the opening of his sixth CPR franchise store in the Greater Dallas-Fort Worth area.

To learn more about CPR Cell Phone Repair Wylie, please visit: http://www.cellphonerepair.com/wylie-tx/

Josh Sevick, CPR’s President stated, “In his role as an Area Representative for CPR, Amin Lakhani has made a huge contribution to our success in the Dallas-Fort Worth marketplace. In addition to his efforts as an Area Representative for CPR, Amin now owns and operates five CPR stores in the Dallas-Fort Worth area. We congratulate Amin and wish him continued success with his CPR franchise ventures.”

Wylie was once a small rural Texas farm town, but is now part of the sprawling Dallas-Fort Worth metroplex. Located just 20 miles northeast of central Dallas, Wylie is conveniently located on State Route 78. While retaining an historic small town appeal, Wylie has grown significantly and now has a population of nearly 46,000 residents. Wylie’s local lakes and dams provide water for towns located in four surrounding counties.

“As I open my fifth store in the Dallas-Fort Worth market in less than two years, it’s clear that there’s a growing demand for CPR’s same day services. In my role as an Area Representative, I focus on expanding CPR’s franchise network by opening new stores in strategic locations that will best meet the needs of our customers. I’m delighted to be opening another new franchise store and look forward to delivering CPR’s professional services to the Wylie community,” added CPR Area Representative Amin Lakhani.

CPR Cell Phone Repair Wylie is located at:

3360 W. FM 544, Unit 20,
Wylie, TX 75098

Please call 469-698-3710 or contact Tech@cpr-wylie.com to learn more about the store’s full range of electronic device repair services.

Please visit the website:

http://www.cellphonerepair.com/wylie-tx/

About CPR Cell Phone Repair

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest growing wireless technology franchise in North America and operates over 300 locations internationally. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets and other personal electronic devices. In both 2016 and 2017 CPR was named in Entrepreneur Magazine’s Franchise 500 List. In 2017 CPR was ranked in the top 100 tier of the List and was ranked #1 in the electronic repairs category. For more information about CPR Cell Phone Repair and franchise opportunities, visit http://www.cellphonerepair.com/ or call 877-856- 5101.

Contact:

Ashley Gooding
agooding@merrymtg.com
216-674-0645 x642

SOURCE: CPR Cell Phone Repair

ReleaseID: 458567